|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-0.13/-0.32
|
企業價值
399.67M
|
資產負債 |
每股賬面淨值
0.27
|
現金流量 |
現金流量率
--
|
損益表 |
收益
156.37M
|
每股收益
0.83
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/11/10 16:56 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same. |